ReviewVaccines2020
Vaccines against Coronaviruses: The State of the Art.
Review in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Vaccine hesitancy in context of COVID-19 in East Africa: systematic review and meta-analysis.BMC public health · 2024Pooled it
- COVID-19 vaccine acceptance and associated factors in 13 African countries: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- COVID-19 vaccine acceptance among pregnant women worldwide: A systematic review and meta-analysis.PloS one · 2022Pooled it
- A cross-sectional study of the predictors of COVID-19 vaccine hesitancy in Pakistan.Human vaccines & immunotherapeutics · 2025Article
- Cross-reactivity IgG, viral load, severity and vaccination outcome as an approach for understanding humoral immune response against SARS-CoV-2.BMC infectious diseases · 2025Article
- Mortality Among Dental Healthcare Workers During the Coronavirus Disease 2019 Pandemic: A Public Domain Database Study.International dental journal · 2025Article
- Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles.Iranian journal of microbiology · 2025Review
- Article
- Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase.Nature communications · 2023Article
- Knowledge and attitude toward the second round of COVID-19 vaccines among teachers working at southern public universities in Ethiopia.Human vaccines & immunotherapeutics · 2022Article
- Exploring vaccine hesitancy determinants during the COVID-19 pandemic: An in-depth interview study.SSM. Qualitative research in health · 2022Article
- Beliefs and barriers of COVID-19 vaccination hesitancy among Sudanese healthcare workers in Sudan: A cross sectional study.Human vaccines & immunotherapeutics · 2022Article
- Public attitudes towards COVID-19 vaccines in Africa: A systematic review.Journal of public health in Africa · 2022Article
- Balancing Benefits and Harms of COVID-19 Vaccines: Lessons from the Ongoing Mass Vaccination Campaign in Lombardy, Italy.Vaccines · 2022Article
- Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit.Avicenna journal of medicine · 2022Article
- Nanoagent-based theranostic strategies against human coronaviruses.Nano research · 2022Review
- Knocking on heaven's door: The gap between health institutions and academies in generating knowledge utilizing real-world data.Frontiers in public health · 2022Article
- Article
- COVID-19 vaccination coverage by company size and the effects of workplace vaccination program in Japan: a cohort study.Environmental health and preventive medicine · 2022Article
- Acceptance of COVID-19 vaccine and associated factors among health professionals working in Hospitals of South Gondar Zone, Northwest Ethiopia.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging epidemic caused by the new coronavirus SARS-CoV-2 represents the most important socio-health threat of the 21st century. The high contagiousness of the virus, the strong impact on the health system of the various countries and the absence to date of treatments able to improve the prognosis of the disease make the introduction of a vaccine indispensable, even though there are currently no approved human coronavirus vaccines. The aim of the study is to carry out a review of the medical literature concerning vaccine candidates for the main coronaviruses responsible for human epidemics, including recent advances in the development of a vaccine against COVID-19. This extensive review carried out on the vaccine candidates of the main epidemic coronaviruses of the past has shown that the studies in animal models suggest a high efficacy of potential vaccines in providing protection against viral challenges. Similar human studies have not yet been carried out, as the main trials are aimed at assessing mainly vaccine safety and immunogenicity. Whereas the severe acute respiratory syndrome (SARS-CoV) epidemic ended almost two decades ago and the Middle East respiratory syndrome (MERS-CoV) epidemic is now better controlled, as it is less contagious due to the high lethality of the virus, the current SARS-CoV-2 pandemic represents a problem that is certainly more compelling, which pushes us to accelerate the studies not only for the production of vaccines but also for innovative pharmacological treatments. SARS-CoV-2 vaccines might come too late to affect the first wave of this pandemic, but they might be useful if additional subsequent waves occur or in a post-pandemic perspective in which the virus continues to circulate as a seasonal virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.